Monday, January 18, 2021
Home Latest Pharma-News XCOPRI (cenobamate tablets) approved by FDA for the treatment partial-onset seizures...

XCOPRI (cenobamate tablets) approved by FDA for the treatment partial-onset seizures in adults

Nov 21, 2019: SK Life Science new option to treat adults with partial-onset seizures, XCOPRI (cenobamate tablets) approved by FDA which has an often difficult-to-control condition that can have a significant impact on patient quality of life.

Seizures occur when group of nerve cells (neurons) in the brain undergo uncontrolled activation generally for short period of abnormal electrical activity in the brain also uncontrolled movements, abnormal thinking or behavior, and abnormal sensations are reported,Movements can be violent, and changes in consciousness can occur.

- Advertisement -

XCOPRI causses Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity also patients with hypersensitivity to cenobamate should avoid XCOPRI. https://fda.einnews.com/pr_news/502878004/fda-approves-new-treatment-for-adults-with-partial-onset-seizures

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1 × 3 =

Most Popular

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...